Close
Help




JOURNAL

Clinical Medicine Insights: Urology

Clinical Use of Tolterodine Extended Release in Overactive Bladder

Submit a Paper


Clinical Medicine Insights: Urology 2012:6 1-9

Published on 23 Apr 2012

DOI: 10.4137/CMU.S6425


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Insights: Urology

Abstract

Overactive bladder (OAB) is a common problem whose prevalence increases with advancing age and compromises health-related quality of life. Tolterodine was the first antimuscarinic drug specifically designed to treat OAB.

Through MEDLINE, we reviewed articles, standardization reports and meeting abstracts, published between 2001 and 2011, on the efficacy and tolerability of Tolterodine extended release (ER). Our search terms included Tolterodine, extended release, overactive bladder, therapeutic use, efficacy, tolerance, and adverse events.

Tolterodine ER, via steady drug release during the daytime, gives the benefit of constant serum concentration and thus better efficacy and tolerability in comparison to Tolterodine immediate release, even in elderly patients with co-morbid conditions.



Downloads

PDF  (508.32 KB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)


Sharing


What Your Colleagues Say About Libertas Academica
It was my great pleasure to serve as a peer reviewer for the Journal of Cell Death. The review process is fast and efficient. The online access was easy and user-friendly. The editorial staff are friendly and helpful. It was a great experience working with Libertas Academica and I look forward to working with them further.
Dr Bebei Cai (San Diego, CA, USA)
More Testimonials

Quick Links


New article and journal news notification services
Email Alerts RSS Feeds
Facebook Google+ Twitter
Pinterest Tumblr YouTube